World Journal of Pharmaceutical and Life Sciences
WJPLS
www.wjpls.org

SJIF Impact Factor: 7.409

IMPACT OF *CESTRUM AURANTIACUM* ON HISTOPATHOLOGICAL INVESTIGATIONS IN FRUCTOSE-INDUCED HYPERTENSIVE RODENTS

Patil Rahul Ravindra[1], Prajakta Maskawade[2], Ragini Bundela*[3], Dr. Karunakar Shukla[4]

[1]PG Scholar, College of Pharmacy, Dr. A.P.J. Abdul Kalam University, Indore MP India.
[2]Assistant Professor, College of Pharmacy, Dr. A.P.J. Abdul Kalam University, Indore MP India.
[3]Associate Professor, College of Pharmacy, Dr. A.P.J. Abdul Kalam University, Indore MP India.
[4]Principal & Professor, College of Pharmacy, Dr. A.P.J. Abdul Kalam University, Indore MP India.

***Corresponding Author: Ragini Bundela**

Associate Professor, College of Pharmacy, Dr. A.P.J. Abdul Kalam University, Indore MP India.

Article Received on 21/04/2024 **Article Revised on 12/05/2024** **Article Accepted on 02/06/2024**

ABSTRACT
The current study intends to investigate the possible impact of *Cestrum aurantiacum* ethanolic leaf extract, which is antioxidant rich, on intestinal motility and histological findings in fructose (10%) induced hypertensive rats. 60 male rodents (weighing 110-150g) were used in the investigation. Rodents were placed into six groups of six, with ten rodents in each group, at random. Group I was used as the standard control group, receiving food pellets and regular water as needed for a period of six weeks. For six weeks, Group II was given a fructose (10%) solution rather than regular water. For 6 weeks, Group III, IV, and V received ECA at varying doses (100, 200, and 400 mg/kg p.o.) in addition to fructose (10%) solution in place of unlimited access to water. For six weeks, Group VI was given a solution of fructose (10%) in place of unlimited access to water and a dose of Enalapril (10mg/kg p.o.). By administering ECA to a solitary strip of rat ascending colon, the cumulative concentration-response curve (CCRC) of Ang II was moved to the right. Compared to the fructose-treated group, ECA administration improved the rat ascending colon's contractile properties in the CCRC of ACh. The histopathological alterations in the fructose (10%) group included sclerotic glomeruli, renal hypertrophy, and hazy swelling in the renal tubules. The liver of the fructose (10%) group had macrovesicular steatosis, fat deposition, and blood sinusoids around the major vein were congested. In the fructose group, the tunica medium thickness was thicker in the aorta. Cardiomyocytes in the heart of the fructose (10%) group are vacuolated. Treatment with ECA lessened the tissue damage caused by fructose as a result of metabolic syndrome. 42.91g of gallic acid equivalent/mg of extract was discovered to be the total phenolic content of ECA. ECA has strong antioxidant effects because it is flavonoid-rich. The outcome shown that ECA may be able to inhibit the development of high blood pressure brought on by fructose by combating oxidative stress brought on by fructose (10%) and lowering Ang II activity.

KEYWORDS: Fructose, *Cestrum aurantiacum* (CA), Metabolic syndrome, Hypertension, Oxidative stress, kidney, Liver, Aorta, Heart.

INTRODUCTION
Hypertension (HT) is a most common cardiovascular disease in developed and developing countries. Due to changes in the man behaviour and life style currently one of the major risk factors for coronary artery disease, cardiac failure, insulin resistance, obesity, strokes, atherosclerosis and renal insufficiency. Many studies have reported diets high in carbohydrates, particularly sugars and even more particularly sucrose and fructose increase the risk of cardiovascular diseases including high blood pressure.[1] A number of scientific reports tend to support the fact some metabolic abnormalities such as hyperinsulinemia, insulin resistance and hypertriglyceridemia as well as hyperactivity of the sympathetic nervous system and oxidative stress were frequently associated with the pathogenesis of sucrose induced hypertension.[2] It is well known that high blood pressure can often lead to dangerous complications if left untreated.[3,4] In developed countries, 10% or more of the total health budget is spent on the management of hypertension, diabetes and its complications. Many synthetic drugs due to their side effects, people largely use herbal medicine because of easily availability, cost effectiveness to prevent and cure illness[5] for curiosity and also the idea that combining it with conventional treatment would help.[6] A holistic or a spiritual health concern and the belief that herbal drugs are natural (and thus safe) also seem to be associated with the use of

alternative medicine.[7] Traditionally, many of the folk remedies of plant origin have long been used for the treatment of various ailments unscientifically exploited or improperly used. Therefore, there is an urgent need to develop new and effective drugs for the treatment of hypertension, can be used as a single plant or in polyherbal formulations. The *Cestrum aurantiacum* belong to the genus Solanaceae family. It is an evergreen, half-climbing shrub originated in South America, India. The *Cestrum aurantiacum* had introduced into China more than on century and it had widely distributed in south China (Guangdong, Fujian, Guangxi, Yunnan) now. Previous phytochemical research on the genus of Cestrumhas revealed that steroidal saponins3, flavonols, terpenoids, lignans as well as phenols are major principles isolated from the plant of this genus.[8-17] With the aim of continuing efforts to identify bioactive natural products from the plants, a chemical investigation on the leaves and stems of *Cestrum aurantiacum* indigenous to the Dali Prefecture of Yunnan Province of China was carried out. A new phenolic compound (1), together with eight known one (2-9) were separated from this plant. In addition, the anti-HIV-1 active and antioxidant activity of (1) were evaluated. The structure elucidation and biological activities of the isolated compounds are also reported. So, the present investigations were undertaken to determine the impact of *cestrum aurantiacum* on histopathological investigations in fructose-induced hypertensive rodents.

MATERIAL AND METHOD

Plant material

Fresh leaves of *cestrum aurantiacum* were purchased locally and authenticated by the Department of Botany, Dr. APJ Abdul Kalam University, Indore (M.P.) and the specimen voucher assigned. After that herbarium file was submitted in Department.

Drugs and chemicals

Fructose, petroleum ether (60-80°C), methanol and gallic acid were obtained from Modern Sciences Pharmaceuticals, Nashik. Acetylcholine (ACh), angiotensinII (AngII), urethane, were obtained from Sigma, Mumbai. Fructose (10%), ACh, AngII and urethane were prepared freshly using distilled water. ECA was dissolved in water and given orally according to the experimental protocol.

Experimental animals

60 Male Albino Wistar Rodents (110-150g) purchased from Mumbai Veterinary college (Mumbai, Maharashtra) were used in the current experimental study. The animals were kept under standard laboratory condition temperature 25 ± 1°C, Relative humidity 45-55 % and Photoperiod (12 h dark/ 12 h light). The protocol of the study was approved by Institutional Animal Ethical Committee (IAEC).

Extraction

Leaves were washed and dried in sunlight. The powder obtained(1kg) was defatted using pet ether (60-80°C) and extracted with ethanol by hot extraction method using soxhlet apparatus. The ethanolic extract obtained was allowed for distillation to remove the excess quantity of ethanol and to concentrate the product into a dry mass. The percent yield value was found to be 12.89 % w/w.[18]

Qualitative phytochemical analysis of plant extract

The *cestrum aurantiacum* extracts obtained was subjected to the preliminary phytochemical analysis following standard methods by Khandelwal and Kokate.[19,20] The extract was screened to identify the presence or absence of various active principles like phenolic compounds, carbohydrates, flavonoids, glycosides, saponins, alkaloids, fats or fixed oils, protein and amino acid and tannins.

Total phenol determination

The total phenolic content of the plant extract was determined using spectrophotometric method (UV-2600, Shimadzu). The reaction mixture was prepared by mixing 0.5 ml of Ethanolic solution of ECA, 2.5ml of 10 % Folin-Ciocalteu's reagent. Blank was concomitantly prepared, containing 0.5ml methanol, 2.5ml of 10% Folin-Ciocalteu's reagent. The samples were then incubated at room temperature for 45 min. The absorbance was recorded at 750 nm. Phenolic contents were measured using a standard curve obtained from various concentrations of gallic acid and expressed as microgram per milligram of gallic acid equivalents.[21]

Experimental protocol

A high fructose diet (fructose 10%, w/v) ad libitum for 6 weeks was used to induce hypertension in male Rodents (150–200g). Every two days, fructose solution was made by dissolving fructose in distilled water.[22] 60 Albino Wistar Rodents were randomly divided in to a group of six, each group containing 10animals. Group I was considered as normal control which received chow pellets and normal drinking water ad libitum for 6 weeks. Group II received fructose (10%) solution instead of normal drinking water for 6 weeks. Group III received fructose (10%) solution instead of drinking water ad libitum and ECA at a dose of 100mg/kg p.o for 6 weeks. Group IV received fructose (10%) solution instead of drinking water ad libitum and ECA at a dose of 200mg/kg p.o for 6 weeks. Group V received fructose (10%) solution instead of drinking water ad libitum and ECA at a dose of 400mg/kg p.o for 6 week. Group VI received fructose (10%) solution instead of drinking water ad libitum and Enalapril at a dose of 10mg/kg p.o for 6 weeks.

Relative organ weight (liver, kidney and heart)

Body weight of each animal was determined before treatment and before sacrifice. The liver, kidney and heart of each animal were dissected and weighed. Relative

organ weight (ROW) was determined by using the formula:

ROW =Absolute organ weight (gm)/ Body weight of the rodents the day of sacrifice (gm) ×100

Measurement of blood pressure by the invasive (direct) method

After the treatment schedule was completed, a subset of five Rodents from each group was used for invasive blood pressure measurements described by Subramani Parasuramanetal.(2012).Urethane (1200 mg/kg, i.p.) was used to anesthetize the rats. For blood pressure measurement left common carotid artery was cannulated using polyethylene tubing which was prefilled with heparinized saline (100 IU/ml) to prevent clotting. The cannula was connected to a pressure transducer by a direct method onto a chart data system (PowerLab4/35; AD Instruments, Australia).[23]

***Invitro* studies**

At the end of the treatment schedule, another subset of five Rodents was sacrificed. Rata sending colon was isolated and used for the cumulative concentration-response curve (CCRC) for Ang II[24] and Ach.[25] The physiological salt solution was made up of the following ingredients: (mM) NaCl, (118); KCl, (4.7); CaCl2, (2.5); MgSO4,(1.2); NaHCO3,(25); KH2PO4,(1.2) and glucose (11). The pH of the physiological salt solution was 7.4, maintained at 37ºC and aerated with carbogen (95 percent oxygen and 5 percent carbon dioxide). One end was attached to an aerator tube, while the other was attached to a lever. Each strip was given the optimum resting tension (1 g) and given 30 mins to equilibrate. The contractile response to each dosage of Ang II and Ach was measured for 60 seconds respectively.

Histopathological study

From individual groups kidneys, liver, aorta, and heart were isolated, weighed and fixed in 10% formalin.

Fixation: The process of autolysis virtually begins immediately after death. Therefore, rapid and adequate fixation after sampling is essential. This can be achieved by immersion of the tissue sample in an adequate volume off ixative solution. There are several methods off ixation including aldehydes, mercurials, alcohols, oxidizing agents, and picric acid derivatives. Tissue immersion in aldehyde (formaldehyde orglutar aldehyde) is the most frequently used fixation method in biomedical research.

Trimming: After fixation, tissue samples need to be properly trimmed to reach the adequate size and orientation of the tissue. This step is also important to reach a sample size that is compatible with subsequent histology procedures such as embedding and sectioning.

Pre-embedding: Pre-embedding is a sequential process that consists of dehydration of tissues in increased concentrations of alcohol solutions, then gradual replacement of alcohol by a paraffin solvent. Xylene has the advantage to be miscible in both alcohol and paraffin. As a result, the tissue sample is dehydrated and fully infiltrated by paraffin.

Embedding: After tissue has been dehydrated, cleared and infiltrated with embedding material like paraffin, agar, gelatin, which is then hardened. The mold is filled with melted paraffin and then immediately placed on a cooling surface. To trace each tissue specimen, the cassette with permanent tissue and study identification is placed on top of the metal base mold and incorporate dint he paraffin block before cooling. In this manner, the cassette will be used as a base of the paraffin block for microtome sectioning.

Sectioning: The objective of this step is to cut 4-5 mm-thick sections from paraffin blocks. The paraffin block is mounted on the microtome holder. Sections are cut as aribbon and are floated on a water bath maintained at45°C to stretch the paraffin section. A standard microscope glass slide is placed under the selected tissue section and removed from the water bath. Tissue sections are then allowed to dry, preferably in a thermostatic laboratory oven at 37°C.

Staining: There are many histochemistry staining techniques that can be applied to examine specific tissue or cells tructures. As most of the sedyes are water soluble, tissue sections should be rehydrated to remove paraffin (using xylene, alcohol solutions ending n water). Hematoxylin and Eosin (H&E) is the routine staining used to study histopathology changes in tissues and organs from animals in toxicity studies. Hematoxylin is a basic dye that has affinity for acid structures of the cell (mostly nucleic acids of the cell nucleus), and eosin is an acidic dye that binds to cytoplasm structures of the cell. As a result, H&E stains nuclei in blue and cytoplasm's in orange-red. After staining, a very thin glass should be placed over the tissue section to protect it and to enhance the optical evaluation of the tissue. This also allows tissue section storage for several years. Cover slipping process consists of gluing the cover slip glass over the tissue section on the microscope slide glass.[26]

Microscopic examination: Light microscopy was used to analyze the sections, and photos were captured at a resolution of 40x.

Statistics

For each group, the mean SEM values were determined. For statistical analysis, one-way ANOVA was performed, followed by Dunnetts multiple compare is on tests. Statistical significance was de fined at a value of $p<0.05$.

RESULTS

Dried and powdered leaves of plant of *Cestrum aurantiacum* was subjected to soxhlation extraction

process with ethanol solvent and yielded 12.89 % w/w. The results of qualitative phytochemical analysis of the crude powder leaf of *Cestrum aurantiacum* were shown in Table 1. Ethanolic extracts of *Cestrum aurantiacum* leaves showed the presence of flavonoids, carbohydrate, proteins and amino acids, saponins, tannins, steroids and alkaloids. The total phenol content of ECA was found to be 42.91µg gallic acid equiv/mg of ECA Figure 1. Chronic administration of ECA (100,200&400mg/kg/day,p.o.) for 6 weeks in fructose (10%) fed rodents significantly ($p<0.05$) shifted the CCRC of Ang-II to the right with suppression of maxima as compared to CCRC of fructose (10%) fed rodents on isolated ascending colon Table 3. Chronic administration of ECA (400mg/kg/day, p.o.) for 6 weeks in fructose (10%) fed Rodents significantly ($p<0.05$) increased percent response of Ach as compared to the CCRC of fructose (10%) fed rats, for the isolated ascending colon Table 4.

Table 1: The phytochemical investigation for various chemical constituents in ECA.

Chemical constituents	Name of the test	Procedure	Observation	Result
Alkaloids	Mayer's test	ECA +few drops of Mayer's reagent	Orange ppt	+++
Tannins	Ferric chloride test	ECA was stirred with 10 mL of hot distilled water, filtered +ferric chloride	blue-green or green precipitate.	+++
Steroids	Salkowski test	ECA +chloroform + a few drops of conc.H2SO4, shacked well and allowed to stand for some time.	Red color appeared at the lower layer	++
Saponins	Frothing test	1ml ECA filterate +1ml distilled water. shake vigorously	Persistent foam which lasted for at least 15 minutes.	++
Flavanoids	Shinoda test	ECA+5ml 95% ethanol+ drops of conc. Hcl+0.5g magnesium turnings	Pink coloration	+++
Carbohydrates	Benedict's test	ECA+5ml benedict's reagent. Boil for 2min and cool.	Red precipitate	+
Protein and amino acids	Ninhydrin test	2-5 drops of Ninhydrin solution were added to ECA and boiled in a water bath for1-2minutes.	Blue colour	++

[+++=highly present,++ =moderately present,+=slightly present]



Fig. 1: Total phenolic content determination of ECA by Folin-Ciocalteu's method.



Fig. 2: Effect of ECA (100, 200 and 400mg/kg p.o., for 6 weeks) on basal MABP (mmHg) in Fructose (10%).

treated hypertensive rats.

Table 2: Effect of ECA (100, 200 and 400mg /kg, p.o., for 6 weeks) on relative organ weight in fructose (10%) treated hypertensive rats.

Group (mg/kg) Parameters	Control	Fructose (10%)	F+ECA (100)	F+ECA (200)	F+ECA (400)	F+Enal (10)
Liver weight (g/100gBW)	3.474 ±0.14	4.464 ±0.20*	3.245 ±0.02#	3.306 ±0.09#	3.163 ±0.13#	2.850 ±0.11#
Heart weight (g/100gBW)	0.389 ±0.02	0.449 ±0.02*	0.371 ±0.004#	0.362 ±0.008#	0.344 ±0.02#	0.304 ±0.01#
Left kidney weight(g/100gBW)	0.391 ±0.02	0.434 ±0.02*	0.361 ±0.004#	0.360 ±0.008#	0.354 ±0.01#	0.308 ±0.009#
Right kidney weight(g/100gBW)	0.395 ±0.02	0.460 ±0.03*	0.384 ±0.01#	0.376 ±0.01#	0.337 ±0.02#	0.311 ±0.01#

All values are expressed as mean ±SEM, n=5. All data are subjected to One Way ANOVA followed by Dunnett's test. * p<0.05 when compared to control and # p<0.05 when compared to the fructose- fed group. ECA= ethanolic extract of *Cestrum aurantiacum,* Enal = Enalapril, F =Fructose (10%). The liver, heart & left kidney weight significantly increased in Rodents fed with fructose (10%) compared to animals in the control group. Liver, heart & left kidney weight significantly decreased in ECA (100,200 &400 mg/kg) treated fructose (10%) fed Rodents (Table 2).

Table 3: Effect of ECA (100, 200 & 400mg /kg /day, p.o.) for 6weeks on CCRC of Ang-II on isolated ascending colon in fructose (10%) fed rats.

Treatment groups (mg/kg)	–Log M concentration of Ang-II % Response and –Log M concentration of Ang-II					
	9.01	8.71	8.41	8.24	8.11	7.81
Control	7.16 ±1.07	13.81 ±1.15	19.43 ±1.28	26.59 ±1.62	31.71 ±1.49	34.78 ±1.80
Fructose (10%)	44.24 ±1.66*	58.82 ±2.91*	75.19 ±3.72*	81.84 ±5.44*	93.35 ±5.17*	100 ±6.99*
ECA (100)	9.20 ±1.24#	15.08 ±0.96#	21.48 ±0.86#	27.10 ±1.65#	34.27 ±2.45#	38.36 ±1.92#
ECA (200)	6.13 ±0.20#	10.23 ±0.70#	17.39 ±0.67#	23.27 ±0.73#	27.87 ±1.06#	31.20 ±1.32#
ECA (400)	6.13 ±0.80#	9.46 ±1.32#	15.08 ±1.68#	20.46 ±0.83#	24.04 ±0.96#	25.57 ±1.22#
Enalapril (10)	5.88 ±0.24#	10.23 ±0.54#	13.55 ±1.02#	16.87 ±1.11#	19.94 ±1.43#	22.76 ±1.15#

All values are expressed as mean ±SEM, n=5.All data are subjected to One Way ANOVA followed by Dunnett's test. *p<0.05 when compared to control and #p<0.05 when compared to fructose fed group.

Table 4: Effect of ECA (100, 200 & 400mg/kg/day, p.o.) for 6 weeks on CCRC of A Chon the isolated ascending colon in fructose (10%) fed rats.

Treatment groups (mg/kg)	% Response and –Log M concentration of ACh					
	4.6	**3.86**	**3.56**	**3.38**	**3.26**	**2.96**
Control	14.87 ±0.91	31.40 ±0.48	50.82 ±1.02	73.96 ±2.03	90.08 ±2.26	100 ±1.56
Fructose (10%)	14.04 ±1.2	20.24 ±1.65*	27.68 ±1.98*	34.71 ±2.49*	40.08 ±2.48*	43.80 ±2.39*
ECA (100)	13.22 ±0.87	24.38 ±1.11	30.57 ±1.35	40.49 ±1.28	48.34 ±1.98	54.54 ±2.29
ECA (200)	9.91 ±1.01	23.55 ±0.67	35.53 ±1.49	42.97 ±1.74	48.34 ±1.07	54.95 ±1.02
ECA (400)	15.70 ±0.24	27.68 ±1.20	52.27 ±0.37#	68.18 ±0.83#	81.40 ±1.86#	92.97 ±1.73#
Enalapril (10)	14.46 ±1.04	26.44 ±1.46	40.08 ±1.93#	49.17 ±1.31#	63.22 ±1.46#	71.90 ±1.93#

All values are expressed as mean±SEM, n=5. All data are subjected to One Way ANOVA followed by Dunnett's test. *

p<0.05 when compared to control and # p<0.05 when compared to fructose fed group.

Kidney histopathology



Fig. 3: A) Kidney of the control groups howed the normal histological picture, normal glomerulus arrow). B) Kidney of Fructose (10%) group showed cloudy swelling in renal tubules (asterisks), sclerotic glomerulus (arrow). C) & D) Kidney of ECA (100&200 mg/kg) treated showed mild cloudy swelling in renal tubules (asterisks), normal glomerulus (arrow). E) &F) Kidney of ECA (400 mg/kg) & Enal (10 mg/kg) group showed normal histological picture, normal glomerulus (arrow). (H&E, X 40). [ECA-Ethanolic extract of *Cestrum aurantiacum*, F- Fructose (10%), Enal-Enalapril.

Liver histopathology



Fig. 4: A) Liver of control Rodents showed normal hepatic lobules and hepatocytes with normal architecture. B) The liver of the Fructose (10%) group showed the presence of macro vesicular steatos is (Black arrows), fat

accumulation (dotted arrow) and congestion of blood sinusoids around the central vein. C) Liver of ECA (100mg/kg) treated showed mild macro vesicul arsteatos is (Black arrows), fat accumulation (dotted arrow) and congestion of blood sinusoids around the central vein. D) Liver of ECA (200 mg/kg) treated showed mild macro vesicular steatos is (Black arrows); fat accumulation (dottedarrow). E) & F) Liver of ECA (400mg/kg) & Enal (10mg/kg)group showed normal hepatic lobules and hepatocytes with normal architecture. (H&E, X 40) [ECA-Ethanolic extract of *Cestrum aurantiacum*, F- Fructose (10%), Enal-Enalapril].

Aorta histopathology



Fig. 5: A)Aorta of control Rodents B)Aorta of Fructose (10%) group showed increased thickness of tunica media (Blackline) C) & D) Aorta of ECA (100 & 200 mg/kg) treated showed the mildly decreased thickness of tunica media (Blackline) E) Aorta of ECA (400 mg/kg) treated showed a normal layer of tunica media (Blackline) D) Aorta of Enal (10 mg/kg) showed the decreased thickness of tunica media (Blackline),(figure: C, D, E, F were compared only with fructose 10% treated group). (H&E, X 40). [ECA-Ethanolic extract of *Cestrum aurantiacum*, F- Fructose (10%), Enal-Enalapril].

Heart histopathology



Fig. 6: A) Heart of the control group shows a normal histological picture. B) Heart of fructose 10% group shows vacuolation of cardiomyocytes (arrows) and mild hyaline degeneration (arrowhead). C), D), E) & F) Heart of

ECA (100,200&400 mg/kg) and Enal 10mg/kg treated showed mild hyaline degeneration (arrow head). (H&E, X 40). [ECA-Ethanolic extract of *Cestrum aurantiacum*, F-Fructose (10%), Enal-Enalapril].

Representative gross images of kidneys



Fig. 7: A) Kidney of the control group. B) Kidney of Fructose (10%) treated group showing hypertrophy. C), D), E) and F) Kidney of ECA (100, 200, &400 mg/kg) and Enal (10 mg/kg) treated groups. (ECA-Ethanolic extract of *Cestrum aurantiacum*, F- Fructose (10%), Enal- Enalapril) Renal hypertrophy is observed in fructose-fed Rodents as compared to the control group .Renal hypertrophy is prevented by ECA(100, 200, &400 mg/kg)and Enalapril (10mg/kg) treatment as compared to fructose treated group.

DISCUSSION

The present study indicates the effect of antioxidant-rich ethanolic extract of *Cestrum aurantiacum* (ECA) on colonic motility and histopathological observations in the fructose (10%) induced hypertensive rats. Flavonoids are a diverse class of bioactive polyphenolic compounds found in a wide variety of dietary plants and herbs. Flavonoids have cardio-vasculo protective properties and may help prevent the development or progression of several cardiovascular disorders, especially hypertension.[27] Consumption of fructose may result in the buildup of advanced glycation end products (AGE) in smooth muscle cells, leading to a change in the contractile activity of the intestinal smooth muscles.[28] It has been found that fructose diet promotes sympathetic activity while decreasing parasympathetic activity.[29] Endothelin-1 (ET-1) and angiotensin II (Ang II), the most powerful vasoconstrictors, are elevated in fructose hypertensive rats, according to L. T. Tran et al. (2009). The presence of a link between the endothelin and renin-angiotensin systems that could influence the development of fructose-induced hypertension is well established.[30] ECA, which is rich in flavonoids, reduces fructose-induced hypertension in rodents by inhibiting the production of ET-1 and Ang II. ECA (100,200,400mg/kg) shifts the CCRC of Ang II to the right, indicating an inhibitory action on Ang II receptors. In the CCRC of ACh the contractile properties of rat ascending colon are increased by ECA (100, 200, 400 mg/kg) treatment as compared to fructose treated group. This indicates an improvement in parasympathetic activity which is decreased in fructose hypertensive rats. The higher ECA dose (400mg/kg) appears to have a greater effect. The kidneys are responsible for long-term blood pressure management, any injury to this organ has the potential to exacerbate or prolong systemic hypertension. Fructose has been shown to have negative effects on renal tissue in various studies. In rats, high fructose consumption causes functional and structural renal impairments that are dose-and time-dependent. Two conditions are likely to have a negative impact on the kidneys: 1) the kidney receives an increased load of fructose by the augmented urinary excretion of this sugar when exposed to higher doses[31] and 2) The first and limiting enzyme in fructose metabolism, fructo kinase (also known as ketohexo kinase or KHK),is highly expressed in renal tissue, particularly in the portion of the proximal tubule.[32] Fructose administration in the food (60%) or drinking water (10%) caused hypertension, hyperuricemia, and hypertriglyceridemia, there is a progressive increase in these parameters as fructose intake increases. Furthermore, fructose causes kidney hypertrophy, glomerular hypertension, cortical vasoconstriction, and pre glomerular arteriolopathy. The elevation in blood pressure was most likely caused by pre glomerular vascular disease and fructose-induced cerebral vasoconstriction.[33] Furthermore, fructose caused proximal tubular hyperplasia, tubular cell proliferation, and focal tubular damage in normal rats, as evidenced by type III collagen deposition in the interstitium, an increase in smooth muscle actin positive myofibroblasts, and arise in macro phage infiltration.[34]

A well-known stimulus that causes vasoconstriction and so promotes systemic hypertension is minor damage to renal tissue.[35] In the present study, kidney of the control group showed the normal histological picture, normal glomerulus. Kidney of Fructose (10%) group showed cloudy swelling in renal tubules, sclerotic glomerulus. Kidney of ECA (100&200mg/kg) treated showed mild cloudy swelling inrenal tubules and normal glomerulus. Kidney of ECA (400mg/kg) & Enal (10mg/kg) groups howed normal histological picture and normal glomerulus. Fructose is linked to biochemical changes that can lead to metabolic syndrome (MetS), non alcoholic fatty liver disease (NAFLD), and type 2diabetes. It is processed by the liver, which induces lipogenesis. Hepatic insulin resistance and dyslipidemia are caused by the triglycerides. The Maillard reaction may be involved in the formation of fructose-derived advanced glycation end products (AGEs). Fructose is ten times more reactive than glucose, but its plasma concentration is just 1% of glucose. Fructose is elevated in several tissues of diabetic patients where the polyol pathway is active, reaching the same order of magnitude as glucose. It's possible that fructose share activity, either directly or through hits metabolites, contributes to intracellular AGE development and vascular complications. Increased fructose consumption has been associated to the development of obesity, dyslipidemia, and impaired glucose tolerance in clinical investigations, and a role in the development of hepatic steatosis hypothesized. Advanced glycation end products (AGEs) are formed when fructose undergoes a nonenzymatic reaction. The liver is the primary organ in which fructose metabolism occurs fast, resulting in increased hepatic synthesis of glycogen and free fatty acids. Nonalcoholic fatty liver disease(NAFLD)is the most frequent condition in industrialized countries,affecting15-20%of the general population. Epidemiological studies have linked NAFLD to excessive fructose consumption. ECA has strong antioxidant characteristics that may help to minimize oxidative stress and prevent the generation of free radicals. In fructose hypertensive rats, administration of ECA (100,200,400 mg/kg) reduced fat deposition in the liver. Liver of control rodents-showed normal hepatic lobules and hepatocytes with normal architecture. The liver of the Fructose (10%) group showed the presence of macro vesicular steatosis, fat accumulation and congestion of blood sinusoids around the central vein. Liver of ECA (100mg/kg) treated showed mild macro vesicular steatosis, fat accumulation and congestion of blood sinusoids around the central vein. Liver of ECA (200mg/kg) treated showed mild macrovesicular steatosis fat accumulation. Liver of ECA(400mg/kg)& Enal (10mg/kg) group showed normal hepaticlobules and hepatocytes with normal architecture. Chronic consumption of high-fructose corn syrup (HFCS) raises uric acid production in the liver. Hypertension is caused by an increase in uric acid levels, which causes oxidative stress and endothelial dysfunction HFCS raises free oxygen radicals and lowers nitric oxide (NO) production. NO synthase activity is also reduced in the aorta of fructose-fed rats. The damage of vascular endothelial cells caused by oxygen free radicals lower NO production and NO synthase activity. Endothelial damage occurs as a result of low NO levels. Hypertension can arise when NO levels are reduced, resulting in decreased vascular relaxation. Kho et al. evaluated histological alterations in the thoracic aorta of high fructose-fed Rodents by staining with H&E. When compared to the control group, the endothelial layers of the thoracic aorta were roughened, layers of the tunica intima media were increased, and adipocytes were hypertrophic. In this study, aorta of Fructose (10%) group showed increased thickness of tunica media. Aorta of ECA(100&200mg/kg)treated showed the mildly decreased thickness of tunica media. Aorta of ECA (400 mg/kg) treated showed normal layer of tunica media. Aorta of Enal (10 mg/kg) showed the decreased thickness of tunica media. Insulin resistance is linked to increased oxidative stress, endothelial dysfunction, and cardiovascular disease.[231] Thus, fructose-rich diets are major cause of heart disease, as indicated by ventricular dilatation and hypertrophy, impaired ventricular contractile performance, and inflammation. The administration of high fructose disrupted the normal histology of rats' kidneys, aorta, and hearts. The fructose group's heart showed mild hyaline degeneration, necrosis, and multifocal regions of mononuclear cell aggregation and cardiomyocyte vacuolation. In this study, heart of the control group showed a normal histological picture. Heart of fructose (10%) groups how vacuolation of cardiomyocytes and mild hyaline de generation. Heart of ECA (100,200&400 mg/kg) and Enal 10mg/kg treated showed mild hyaline degeneration. ECA has potent antioxidant properties, which may reduce oxidative stress, ands uppers free radical formation. In fructose hypertensive rats, administration of ECA(100,200,400 mg/kg) reduced fat deposition in the liver, reduced aortic wall thickening, and prevented glomerulosclerosis and cardiomyocyte vacuolation. ECA (100,200,400 mg/kg) has shown a protective effect on histology of kidney, liver, aorta and heart as compared to fructose (10%) treated rats. The metabolic syndrome caused by fructose is linked to glomerular hypertension and renal microvascular abnormalities in rats. In fructose (10%) fed rats, glomerular hypertension, renal hypertrophy and cortical vasoconstriction are all indicators of renal dysfunction. Renal hypertrophy was seen in fructose-fed Rodents compared to control rats ,and it was reversed by ECA (100,200,400 mg/kg) and enalapril (10 mg/kg) administration. Thus, ECA has antioxidant activity and reverses metabolic syndrome in fructose induced hypertensive rat model.[36-57]

CONCLUSION

Ethanolic leaf extract of *Cestrum aurantiacum* (ECA) could prevent the development of hypertension in Rodents caused by fructose (10%), probably by battling oxidative stress caused by fructose and Ang II, as well as decreasing Ang II activity. The histopathological studies also revealed the protective effect of ECA on

kidney, liver, aorta and heart. The effect appeared to be more pronounced at a dose of ECA 400 mg/kg.

REFERENCES

1. Parks EJ, Hellerstein MK. Carbohydrate-induced hyper triacylglycerolemia: historical perspective and review of biological mechanisms. Am J Clin Nutr., 2000; 71: 412-33.
2. Fried SK, Rao SP. Sugars, hypertriglyceridemia and cardiovascular disease. Am J Clin Nutr., 2003; 78: 873-80.
3. Badyal DK, Lata H, Dadhich AP. Animal models of hypertension and effect of drugs. Indian J Pharmacol., 2003; 35: 349-62.
4. Deep Raj Paul, Kartika Paul. Diabetes mellitus and its complications: a review. Int J Curr Pharm Res., 2012; 4: 12-7.
5. Noumi E, Houngue F, Lontsi D. Traditional medicines in primary health care: plants used for the treatment of hypertension in Bafia, Cameroon. Fitoterapia, 1999; 70: 134-9.
6. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Seminars Integrative Med., 2004; 2: 54-71.
7. Bishop FL, Yardley L, Lewith GT. A systematic review of beliefs involved in the use of complementary and alternative medicine. J Health Psychol, 2007; 12: 851-67.
8. Z.X. Chen and X.K. You,Chin. J. Food. Sci., 2002; 23: 110.
9. Z.X. Chen and X.F. Tang, Chin. J. Herb. Med., 2002; 33: 976.
10. M.A. Fouad, K.M. Mohamed, M.S. Kamel, K. Matsunami and H.Otsuka, J. Nat. Med., 2008; 62: 168.
11. M. Haraguchi, Y. Mimaki, M. Motidome, H. Morita, K. Takey a, H.Itokawa, A. Yokosuka and Y. Sashida, Phytochemistry, 2000; 55: 715.
12. Y. Zhang, H.Z. Li, Y.J. Zhang, R.M. Jaco, S.I. Khan, X.C. Li and C.R.Yang, Steroids, 2006; 71: 712.
13. Y. Mimaki, K. Watanabe, Y. Ando, C. Sakuma, Y. Sashida, S. Furuyaand H. Sakagami, J. Nat. Prod., 2001; 64: 17.
14. B. D'Abrosca, M. Dellagr eca, A. Fiorentino, P. Monaco, A. Natale, P.Oriano and A. Zarrelli, Phytochemistry, 2005; 66: 2681.
15. B. D'Abrosca, M. Dellagr eca, A. Fiorentino, A. Golino, P. Monacoand A. Zarrelli, Nat. Prod. Res., 2006; 20: 293.
16. F. Antonio, D.G. Marina, D.A. Brigida, O. Palma, G. Annunziata, I. Angelina, Z. Armando and M. Pietro, Biochem. System. Ecol., 2007; 35: 392.
17. B. Abrosca, G.M. Della, A. Fiorentino, P. Monaco and A. Zarrelli, J. Agric. Food. Chem., 2004; 52: 4101.
18. Mukherjee PK. Quality control of herbal drugs. 2nd Ed. Business Horizons, 2007.
19. Khandelwal KR. Practical pharmacognosy technique and experiments. 23rd Ed. Nirali Prakashan, 2005.
20. Kokate CK. Practical pharmacognosy. 4th Ed. Vallabh Prakashan, 1994.
21. Olufunmiso OO, Afolayan AJ, Phenolic content and antioxidant property of the bark extract of *Ziziphus mucronata* willd. Subsp. mucronata willd, BMC Complement *Alternative Medicine,* 2011; 11: 130.
22. Fakhoury-Sayegh N, Trak-Smayra V, Sayegh R, Haidar F, Obeid O, Asmar S, Khazzaka A. Fructose threshold for inducing organ damage in a rat model of nonalcoholic fatty liver disease. Nutrition research, Feb. 1, 2019; 62: 101-12.
23. Rathee JS, Hassarajani SA, Chattopadhyay S. Antioxidant activity of Cestrum aurantiacumleaf extract. Food chemistry, Jan. 1, 2007; 103(4): 1350-7.
24. Sharma A, Patel S. Preliminary phytochemical analysis of Ethanolic and aqueous extractofmedicinalplant-Cestrum aurantiacumLinn. Worldj. pharm. pharm. sci., Sep. 16, 2016; 5(11): 1393-401. doi: 10.20959/wjpps201611-8091
25. YadavRN, AgarwalaM. Phytochemicalanalysisofsomemedicinalplants. J. Phytol, Dec. 14, 2011; 3(12).
26. MishraAK, UpadhyayR, ChaurasiaJK, TiwariKN. Comparative antioxidantstudy in different flower extracts of Cestrum aurantiacum(L.)(Oleaceae): an important medicinal plant. Rev. Bras. Bot., Sep. 2016; 39(3): 813-20.
27. Bursać BN, Djordjevic AD, Vasiljević AD, Milutinović DD, Veličković NA, Nestorović NM, Matić GM. Fructose consumption enhances glucocorticoid action in rat visceral adipose tissue. J. Nutr. Biochem, Jun 1, 2013; 24(6): 1166-72. doi:https://doi.org/10.1016/j.jnutbio.2012.09.002
28. Parasuraman S, Raveendran R. Measurement of invasive blood pressure in rats. J Pharmacol Pharmacother, Apr. 2012; 3(2): 172. doi: 10.4103/0976-500X.95521
29. RegoliD, VaneJR. Asensitivemethodfortheassayofangiotensin. BrJPharmacol Chemother, Oct. 1964; 23(2): 351-9. doi: https://doi.org/10.1111/j.1476-5381.1964.tb01591.x
30. Nakahata N, Nakanishi H, Suzuki T. Depressive effect of epinephrine mediated via adrenergicbeta-receptorinisolatedratcolonandduodenum.Jpn.J.Pharmacol, 1977; 27(3): 341-9. doi:https://doi.org/10.1254/jjp.27.341
31. Slaoui M, Fiette L. Histopathology procedures: from tissue sampling to histopathological evaluation. InDrug safety evaluation, 2011; 69-82. doi: 10.1007/978-1- 60761-849-2_4
32. Maaliki D, Shaito AA, Pintus G, El-Yazbi A, Eid AH. Flavonoids in hypertension: a brief review of the underlying mechanisms. Current opinion in pharmacology, Apr. 1, 2019; 45: 57-65.
33. Georgiev TK, Tolekova AN, Genov NV, Pashova-Stoyanova LZ, Tsokeva ZI, Nancheva KG, Sandeva RV, Ilieva GS, Ganeva MG, Hadzhibozheva PV. Metabolic disorders induced

by fructose-drinking water affect angiotensin II-mediated intestinal contractility in male Wistar rats. Folia Med., 2020; 62(4): 802-11.
34. DosSantosF, Moraes-SilvaIC, MoreiraED, IrigoyenMC. Theroleofthebaroreflex and parasympathetic nervous system in fructose-induced cardiac and metabolic alterations. Sci. Rep., Jul20, 2018; 8(1): 1-9.
35. Tran LT, Yuen VG, McNeill JH. The fructose-fed rat: a review on the mechanisms of fructose-induced insulin resistance and hypertension. Mol. Cell. Biochem, Dec., 2009; 332(1): 145-59.
36. Kizhner T, Werman MJ:Long-term fructose intake: biochemical consequences and altered renal histology in the male rat. Metabolism, 2002; 51: 1538–1547.
37. Diggle CP, Shires M, Leitch D, et al.: Ketohexokinase: expression and localization of the principal fructose-metabolizing enzyme. J Histochem Cytochem, 2009; 57: 763–774.
38. Sanchez-Lozada LG, Tapia E, Jimenez A, et al.: Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. Am J Physiol Renal Physiol, 2007; 292: F423–F429.
39. Nakayama T, Kosugi T, Gersch M, et al.: Dietary fructose causes tubulointerstitial injury in the normal rat kidney. Am J Physiol Renal Physiol 2010, 298:F712–F720.Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B: Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med., 2002; 346: 913–923.
40. Gugliucci A. Formation of fructose-mediated advanced glycation end products and their roles in metabolic and inflammatory diseases. Adv. Nutr., Jan. 2017; 8(1): 54-62.
41. MastrocolaR, CollinoM, RogazzoM, MedanaC, NigroD, BoccuzziG, AragnoM. Advanced glycation end products promote hepatosteatosis by interfering with SCAP- SREBPpathwayinfructose-drinkingmice. Am.J. Physiol.-Gastrointest. Liver Physiol, Sep. 15, 2013; 305(6): G398-407.
42. TappyL, LêKA. Metabolic effects of fructose and the world wide increase in obesity. Physiol Rev., 2010; 90: 23–46.
43. Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-JadidiR, Dawnay A. Quantitative screening of advanced glycationendproducts in cellular and extracellular proteins by tandem mass spec-trometry. Biochem., 2003; J375: 581–592.
44. OuyangX, CirilloP, SautinY, McCallS, BruchetteJL, DiehlAM, JohnsonRJ, Abdelmalek MF. Fructose consumption as a risk factor fornon-alcoholic fatty liver disease J. Hepatol, 2008; 48: 993–999.
45. Thuy S, Ladurner R, Volynets V, Wagner S, Strahl S, Königsrainer A,Maier KP, Bischoff SC, Bergheim I. Nonalcoholic fatty liver disease inhumans is associated with increased plasma endotoxin and plasminogenactivator inhibitor 1 concentrations and with fructose intake.J Nutr1, 2008; 38: 1452–1455.
46. de Oliveira, EP, Burini, RC. High plasma uric acid concentration: causes and consequences. Diabetol Metab Syndr, 2012; 4: 12.
47. Kim, SY, Guevara, JP, Kim, KM.Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum, 2009; 61(7): 885–892.
48. Aroor, AR, Mandavia, CH, Sowers, JR. Insulin resistance and heart failure: molecular mechanisms. Heart Fail Clin., 2012; 8(4): 609–617.
49. Jalal, DI, Chonchol, M, Chen, W. Uric acid as a target of therapy in CKD. Am J Kidney Dis., 2013; 61(1): 134–146.
50. Mazzali, M, Hughes, J, Kim, YG. Elevateduricacidincreasesbloodpressureinthe rat by a novel crystal-independent mechanism. Hypertension., 2001; 38(5): 1101–1106.
51. Nyby, MD, Abedi, K, Smutko, V. Vascular Angiotensin type 1 receptor expression is associated with vascular dysfunction, oxidative stress and inflammation in fructose-fed rats. Hypertens Res., 2007; 30(5): 451–457.
52. Busserolles, J, Gueux, E, Rock, E.Oligofructose protects against the hypertriglyceridemic and pro-oxidative effects of a high fructose diet in rats. J Nutr., 2004; 133(6): 1903–1908.
53. Shinozaki, K, Ayajiki, K, Nishio, Y. Evidence for a causal role of the renin- angiotensin system in vascular dysfunction associated with insulin resistance. Hypertension, 2004; 43: 255–262.
54. Miatello, R, Risler, N, Castro, C. Aortic smooth muscle cell proliferation and endothelialnitricoxidesynthaseinfructose-fedrats. AmJ Hypertens, 2001; 14(11Pt 1): 1135–1141.
55. Baldus, S, Koster, R, Chumley, P. Oxypurinol improves coronary and peripheral endothelial function in patients with coronary artery disease. Free RadicBiol Med., 2005; 39(9): 1184–1190.
56. Kanellis, J, Kang, DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol, 2005; 25(1): 39–42.
57. Conti, V, Russomanno, G, Corbi, G. Adrenoreceptors and nitric oxide in the cardiovascular system. Front Physiol 2013; 4: 321.